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Abstract
Background: Overproduction of pro-inflammatory cytokines is a well established factor in the progression of chronic heart
failure (CHF). Changes in cellular immunity have not been widely studied, and the impact of standard medication is
uncertain. Here we investigate whether a leukocyte redistribution occurs in CHF and whether this effect is influenced by
beta-blocker therapy.
Methodology: We prospectively studied 75 patients with systolic CHF (age: 68611 years, left ventricular ejection fraction
32611%, New York Heart Association class 2.560.7) and 20 age-matched healthy control subjects (age: 63610 years). We
measured the response of cells to endotoxin exposure in vitro, analysed subsets of lymphocytes using flow cytometry, and
assessed plasma levels of the pro-inflammatory markers interleukin 1, 6, tumor necrosis factor-a, and soluble tumor necrosis
factor receptors 1 and 2.
Principal findings: While no differences in the number of leukocytes were noted between patients with CHF and healthy
controls, we detected relative lymphopenia in patients with CHF (p,0.001 vs. control), mostly driven by reductions in T
helper cells and B cells (both p,0.05). The number of neutrophils was increased (p,0.01). These effects were pronounced in
patients who were beta-blocker naı ¨ve (32% of all patients with CHF). Increased plasma levels of soluble tumor necrosis
receptor-1 correlated with the relative number of lymphocyte subsets.
Conclusions: In patients with CHF, we detected a redistribution of leukocyte subsets, i.e. an increase in neutrophils with
relative lymphopenia. These effects were pronounced in patients who were beta-blocker naı ¨ve. The underlying mechanism
remains to be elucidated.
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Introduction
Chronic heart failure (CHF) is a multisystem disorder that affects
not only the cardiovascular system but many other body organs and
functions. The involvement of these systems can be explained by
overproduction of neuroendocrine mediators and cytokines, which
are a key mechanism for the progression of CHF. Elevated levels of
catecholamines, among others, have long been recognized to play a
role in this syndrome [1]. Both noradrenaline and adrenaline,
released from nonsynaptic varicosities and the adrenal medulla,
respectively, have profound effects on the immune system [2]. This
may be of particular interest in heart failure, because evidence has
accumulated over the last two decades to demonstrate convincingly
that this disease represents a state of chronic inflammation [3].
Thus, modulation of inflammatory mediators and the cells from
which they originate has become a focus of research in recent years
[4]. Pro-inflammatory cytokines such as tumor necrosis factor-a
(TNFa) and interleukin (IL) 1 and 6, have been shown to be
independent predictors of poor survival in CHF [5,6].
Few studies have investigated the interplay between pro-
inflammatory cytokines and the redistribution of leukocyte subsets
in patients with CHF and no studies have sought to elucidate the
role of standard medical therapy. We measured the distribution of
leukocyte subsets and their relation to markers of inflammatory
activation in patients with CHF. We also assessed the impact of
treatment with b-blockers, angiotensin-converting enzyme (ACE)
inhibitors, angiotensin receptor blockers (ARB), aldosterone
antagonists, and statins.
Materials and Methods
Study population
We prospectively studied 75 patients with CHF who were
recruited from the Royal Brompton Hospital outpatients’ depart-
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CHF was based on symptoms, clinical signs, and documented left
ventricular impairment measured by echocardiography (left ventric-
ular ejection fraction#45%). All patients were on unchanged
medication for at least four weeks. At the time of assessment no
patientsweretakingnon-steroidalanti-inflammatorydrugsorsteroid
hormones. Subjects with clinical signs of infection, rheumatoid
arthritis, or cancer were excluded. In addition, we enrolled 20 age-
matched healthy control subjects (patients’ relatives and hospital
staff). At the time of assessment none of the control subjects were
taking any medication. The ethics committee on human research of
the Royal Brompton Hospital, London, UK, approved the study,
and all subjects provided written informed consent. The study was
performed in adherence to the Declaration of Helsinki.
Fluorescence activated cell sorting (FACS) analysis
Venous EDTA blood was drawn after 15 minutes of semi-
supine rest in the morning. Samples of 100 ml were incubated for
25 minutes at +4uC in the dark with the respective antibody
combinations. Red blood cells were lysed using FACS lysing
solution (Becton Dickinson, Oxford, UK) according to the
manufacturer’s instructions. Cells were then washed using
phosphate buffered saline (PBS), supplemented with 2% fetal calf
serum and 0.01% sodium azide (all from Sigma-Aldrich, Poole,
UK). 30,000 cells were analysed per sample using a FACSort
H and
CellQuest
H software (both from Becton Dickinson). The following
antibodies (with the respective isotype controls) were used in the
following combinations: (i) fluorescein isothiocyanate (FITC)
labelled monoclonal mouse-anti-human CD4 IgG1 antibody (Ab)
(Sigma-Aldrich)/R-phycoerythrin (PE) labelled monoclonal
mouse-anti-human CD8 IgG2a Ab (Sigma-Aldrich)/Peridinin-
chlorophyll-protein Complex (PerCP) labelled monoclonal
mouse-anti-human CD3 IgG1 Ab (Becton Dickinson), (ii) FITC
labelled monoclonal mouse-anti-human CD14 IgG2a Ab (Sigma-
Aldrich)/PE labelled monoclonal mouse-anti-human CD19 IgG1
Ab (Sigma-Aldrich), (iii) PE labelled monoclonal mouse-anti-
human HLA-DR IgG2a Ab (BD PharMingen). In addition, an
untreated (i.e. no Ab staining) sample was analysed for each
patient.
Whole blood culture and lipopolysaccharide treatment
A substudy was performed in 42 patients with CHF and 11
healthy controls of the above described cohort. Venous citrated
blood was drawn as described above. Whole blood samples were
diluted 1:1 with RPMI 1640 (Life Technologies Ltd., Paisley, UK)
supplemented with 10 U/mL heparin (Leo Laboratories Ltd.,
Bucks, UK). Afterwards, 1 mL aliquots were placed in 1.5 mL
Eppendorf tubes (Eppendorf UK Ltd., Cambridge, UK). E. coli-
derived LPS (serotype 0111:B4, Sigma-Aldrich Co. Ltd., Irvine,
U.K.) was added to achieve a final concentration of 0.1, 1, 10, or
100 ng/mL. LPS was diluted in RPMI 1640. The addition of
RPMI 1640 alone served as a control. Dilutions, aliquoting and
stimulations were carried out under sterile conditions. Following
the addition of endotoxin (lipopolysaccharides, LPS), all samples
were incubated for 6 hours in a humidified atmosphere (37uC, 5%
CO2). Pilot experiments had demonstrated a maximal TNFa
secretion after 6 hours incubation (data not shown). Upon
centrifugation, supernatants were harvested and frozen immedi-
ately at 280uC for later analysis. Cell viability was.90% as
assessed using trypan blue exclusion.
Detection of TNFa and IL-6 from culture supernatant
The detection of TNFa and IL-6 was performed using standard
enzyme-linked immunosorbent assay (ELISA) kits according to the
manufacturer’s instructions (R & D Systems, Minneapolis, USA).
The detection limit was 15 pg/mL. All samples were frozen at
280uC until analysis.
Detection of plasma cytokines and cytokine receptors
Serum levels of TNFa, soluble TNF receptor-1 and 2 (sTNFR-1
and sTNFR-2), IL-6, and IL-1b were determined using the
respective Quantikine HS immunoassay kits (all from R&D,
Minneapolis, USA). The lower limits of detection are 0.106 pg/
mL, 7.8 pg/mL, 7.8 pg/mL, 0.039 pg/mL, and 0.057 pg/mL,
respectively.
Statistical analysis
Data are presented as mean6SD. All data were checked for
normal distribution using the Kolmogorov-Smirnov test. Non-
normally distributed variables were log-transformed to achieve
normal distribution before further analysis. Analysis of variance
(ANOVA) with Fisher’s post hoc test, repeated measures ANOVA,
Student’s unpaired and paired t-tests, simple regression, and the
chi-square test were used as appropriate. The effect of beta-blocker
therapy was assessed using the ANOVA method of testing. A p-
value,0.05 was considered significant.
Results
Study population
There were no significant differences between healthy control
subjects and patients with CHF in terms of age, sex, weight,
number of smokers, or body mass index. As expected there were
differences in standard biochemistry (Table 1). Patients with
CHF presented with significantly lower total cholesterol
(p,0.0001) and high density lipoprotein cholesterol levels
(p=0.0003). They had lower hemoglobin (p=0.02) and higher
creatinine and uric acid levels (both p,0.0001 vs. control,
Table 1). CHF patients (n=75) were on standard medication for
their condition with diuretics (95%), angiotensin converting
Table 1. Baseline data for control subjects and patients with
CHF.
Controls CHF Patients p-Value
Number (female) 20 (8) 75 (16) 0.09
NYHA class 2.560.7
Aetiology (ischemic/non-ischemic, %) 65/35
LVEF (%) 31.9611.1
Age (yr) 63.3610.1 67.8610.7 0.09
BMI (kg/m
2) 26.463.0 28.965.4 0.26
Hemoglobin (g/dL) 14.561.1 13.561.7 0.02
Sodium (mmol/L) 13962 13764 0.01
Potassium (mmol/L) 4.360.3 4.360.5 0.4
Creatinine (mmol/L) 83615 124644 ,0.0001
Alkaline phosphatase (U/L) 66617 76633 0.18
Aspartate transaminase (U/L) 28616 23610 0.18
Gamma glutamyl transpeptidase (U/L) 34626 55648 0.03
Uric Acid (mmol/L) 321679 4566130 ,0.0001
Cholesterol (mmol/L) 6.060.7 4.761.2 ,0.0001
High density lipoprotein (mmol/L) 1.560.4 1.160.3 0.0003
doi:10.1371/journal.pone.0006411.t001
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(ARB) (28%), b-blockers (68%), aldosterone antagonists (57%),
and statins (64%). 51 CHF patients received beta-blockers, and
the following beta-blockers were prescribed: 39% bisoprolol
(n=20), 59% carvedilol (n=30), 2% metoprolol (n=1). Five
CHF patients(2 in the group receivingb-blockers) werenot being
treated with either an ACE-inhibitor or an ARB. Apart from b-
blockers, statistical differences in regard to the distribution of the
patients’ medication were not observed (beta-blocker naı ¨ve vs.
beta-blocker treated patients, n.s. for all comparisons). A total of
16 patients with CHF had died before December 2007 when the
database was censored.
LPS stimulations and serum cytokine levels
Whole blood from both healthy subjects and patients with CHF
produced substantial levels of TNFa and IL-6 when stimulated
with 0.1, 1, 10, or 100 ng/mL LPS (Figure 1). There was a trend
towards higher LPS-stimulated TNFa production levels in patients
with CHF than in healthy control subjects at two LPS
concentrations, 0.1 (p=0.05) and 1 ng/mL (p=0.06). There
was no significant difference with regards to the serum
concentrations of C-reactive protein, IL-1b, and TNFa (all
p.0.25, Table 2). There were significantly higher levels of IL-6
(p,0.0001), soluble TNFa receptor (sTNFR) 1 (p=0.0025), and
sTNFR-2 (p=0.0007, Table 2).
Distribution of leukocyte subsets
There were no significant differences in the absolute number of
white blood cells between healthy control subjects and patients with
CHF (p=0.39, Figure 2A). No differences in either the absolute or
in the relative numbers were noted for monocytes (control:
0.3560.09610
9/L or 4.961.1%; CHF: 0.3860.12610
9/L or
5.261.6%, both p.0.3), eosinophils (control: 0.2360.09610
9/L
or3.161.5%;CHF: 0.2660.17610
9/Lor3.562.2%,bothp.0.4),
or basophils (control: 0.0860.04610
9/L or 0.960.5%; CHF:
0.0760.05610
9/L or 0.860.4%, both p.0.2). However, both the
absolute and the relative number of neutrophils were increased in
patients with CHF (control: 4.261.2610
9/L; CHF: 5.061.6610
9/
L, p=0.048, Figure 2B). Additionally, the absolute and the relative
number of lymphocytes was decreased in these patients (control:
2.160.6610
9/L; CHF: 1.760.7610
9/L, p=0.019, Figure 2C).
The distribution of lymphocyte subsets in healthy control subjects
and patients with CHF is given (Figure 3).
Correlation analysis
Significant negative correlations existed between serum levels of
sTNFR-1 and the relative number of lymphocytes, CD3
+ T cells,
T helper cells, B cells, and HLA-DR expressing lymphocytes
(Table 3). Similarly, there was a negative correlation between
sTNFR-2 and the relative number of lymphocytes and HLA-DR
expressing lymphocytes (Table 3). There was a trend towards a
negative correlation between sTNFR-2 and T helper cells
(p=0.06) and B cells (p=0.08). Similar observations were made
for IL-6, but not for IL-1b, TNFa, and CRP (Table 3). Significant
positive correlations were detected between serum creatinine levels
and sTNFR-1, sTNFR-2, and IL-6.
Effect of patients’ medication
We tested the effects of the patients’ medication with
angiotensin converting enzyme inhibitors/angiotensin receptor
blockers, b-blockers, aldosterone antagonists, and statins on
lymphocyte and neutrophil distribution, because these leukocyte
populations were significantly different between healthy subjects
and patients with CHF. Whilst beta-blockers had significant effects
on the distribution pattern, no such effect was noted with
angiotensin converting enzyme inhibitors/angiotensin receptor
Figure 1. LPS-stimulated production of TNFa (panel A) and IL-6 from whole blood from healthy control subjects (n=11, black line)
and patients with CHF (n=42, gray line). * vs. unstimulated control (0 ng/mL LPS); 1 vs. 0.1 ng/mL LPS; { vs. 1 ng/mL LPS; # vs. 10 ng/mL LPS.
One symbol denotes p,0.05, two symbols p,0.01, three symbols p,0.001, four symbols p,0.0001.
doi:10.1371/journal.pone.0006411.g001
Table 2. Baseline marker of immune activation and cytokines.
Control Subjects CHF Patients p-Value
White Blood Cells (610
9/L) 7.061.6 7.562.1 0.39
CRP (mg/L) 8.365.6 10.167.5 0.28
IL-1b (pg/mL) 1.161.7 1.263.0 0.96
IL-6 (pg/mL) 2.262.5 4.964.2 ,0.0001
TNFa (pg/mL) 4.268.4 2.062.4 0.43
TNFR-1 (pg/mL) 12526319 208661082 0.0025
TNFR-2 (pg/mL) 15916466 278061360 0.0007
doi:10.1371/journal.pone.0006411.t002
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results for b-blockers are presented in Table 4.
Discussion
Our data show that the distribution of lymphocyte subsets and
neutrophils is significantly altered in patients with CHF as
compared to healthy age-matched controls. Whilst no change in
the absolute number of white blood cells was noted, we found
decreases in the number of lymphocytes, mainly driven by
reductions in T helper cells and B cells. These effects were most
pronounced in b-blocker naı ¨ve patients who also presented with
lower relative numbers of cytotoxic T cells as compared to patients
who were on such a drug (Table 4). Thus, it appears that b-
blockers are able to reverse changes in leukocyte distribution seen
in patients with CHF.
In view of these findings, one possible explanation for
leukocyte redistribution, among others, is linked to elevated
levels of catecholamines, which have been described by many
independent researchers in patients with CHF [7,8,9,10]. Since
virtually all lymphoid cells express b-adrenergic receptors [2],
catecholamines exert direct effects on these cells. b2-adrenergic
receptors are most abundantly expressed, but their number and
their sensitivity vary significantly between cell types [11].
Experimental catecholamine administration is known to yield
two distinct responses: an early mobilization of lymphocytes that
occurs within minutes is followed by an increase in granulocytes
with relative lymphopenia, which occurs after a few hours [12].
The picture in our patients with CHF might represent this late
phase of catecholamine exposure. Moreover, our findings are in
line with those from earlier reports that demonstrated that
adrenaline injection induced the most profound changes in the
fraction of T- and B-lymphocytes [13,14]. Treatment of healthy
volunteers with terbutaline, a selective b2-agonist, has been
shown to decrease the number of circulating lymphocytes mainly
in those subsets with the greatest b-adrenergic sensitivity in vitro
[15]. This effect has been ascribed to the inhibition of
lymphocyte proliferation [16]. Most catecholamine-induced
effects appear to be mediated via b2-adrenergic receptors but,
it has also been reported that increases in granulocytes involve b-
adrenergic receptor stimulation [12]. Thus, distinct mechanisms
lead to the recruitment of different immune cells. From a
Figure 2. Distribution of leukocytes (panel A) and their subsets (panels B and C) in healthy control subjects (n=20) and patients
with CHF (n=75).
doi:10.1371/journal.pone.0006411.g002
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survival that acute stress (which triggers catecholamine release)
induces a recruitment of cells active in the first line of
immunologic defence, i.e. an early increase in non-specific
granulocytes [12]. However, we did not measure catecholamine
levels as this was beyond the scope ofthis study. Nevertheless, this
is a limitation of the study and catecholamine levels should be
assessed in future analyses.
Alternatively, higher cortisol levels may be responsible for the
observed effects in patients with CHF. Cortisol may induce
granulocytosis and relative lymphopenia. Moreover, disturbed
intestinal microcirculation and barrier function in CHF may
induce a state of chronic endotoxinemia which may yield
lymphopenia.
Nevertheless, a vast array of factors contributes to the release of
catecholamines in patients with CHF, and one important factor is
the influence of pro-inflammatory cytokines. It was shown decades
ago that IL-1, IL-6, and TNFa can trigger the activation of the
sympathetic nervous system in the brain [2]. Peripheral injection
of IL-1b, for example, produces a long-lasting increase in the
activity of the sympathetic nerves of the spleen, which in turn
yields an increase in the release of noradrenaline from this organ
[17]. Pro-inflammatory cytokines are activated earlier in the
course of CHF than the classic neurohormones like angiotensin II
or noradrenaline [18,19]. This buttresses their preeminent role in
the progression of CHF. We found significant correlations between
most lymphocyte subsets that we investigated and sTNFR-1,
sTNFR-2 but not TNFa itself (Table 3). This finding is in line with
earlier reports, which found that plasma concentrations of soluble
TNFa receptors vary less than those of TNFa [20]. TNFa has also
been shown to provoke renal dysfunction, which is the most likely
explanation for the association between creatinine and the plasma
levels of both soluble TNFa receptors (Table 3) [21].
Some limitations of this analysis demand further discussion,
among these the fact that the number of study patients is rather
limited. Moreover, our results may be influenced by the fact that
the patients not receiving b-blockers might have been sicker which
may have led physicians not to prescribe b-blockers as eg. they had
a lower blood pressure. Furthermore, as stated before, we did not
assess catecholamine levels. As chronic lymphopenia may
theoretically yield an increased rate of infection, it is tempting to
speculate that the mortality benefit provided by the use of b-
blockers in CHF may in part be explained by the effects observed
here. This, however, needs to be interpreted with caution. The
results presented here need to be confirmed in a larger analysis.
In conclusion, we found a significant redistribution of leukocyte
subsets with an increase in granulocytes and relative lymphopenia
in patients with stable CHF. This finding is in line with previous
studies [18,22] that were performed before b-blockers were
implemented into the treatment guidelines of CHF. An association
Figure 3. Distribution of lymphocyte subsets in healthy control subjects (n=20) and patients with CHF (n=75).
doi:10.1371/journal.pone.0006411.g003
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be speculated that beta-blockers partly reverse the CHF-associated
leukocyte redistribution. Elevated levels of pro-inflammatory
cytokines may be responsible for this phenomenon, because they
are known to trigger catecholamine-release via stimulation of the
sympathetic nervous system in the brain.
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Table 4. Effect of b-blockers.
Control Subjects (n=20)
CHF Patients on a
Beta-Blocker (n=51)
CHF Patients without a
Beta-Blocker (n=24)
p-Value for
Trend (#)
White Blood Cells (610
9/L) 7.061.6 7.562.1 7.462.2 0.67
Lymphocytes (%) 30.266.3 25.267.4 {{ 16.865.1 {{{{ **** ,0.0001
CD3
+ T cells (%) 17.566.4 16.365.9 10.564.1 {{{ *** ,0.0001
CD4
+ T helper cells (%) 11.664.3 10.663.8 7.062.7 {{{ *** 0.0001
CD8
+ cytotoxic T cells (%) 4.962.8 4.863.3 2.961.8 {{ ** 0.008
CD19
+ B cells (%) 4.262.6 2.861.9 {{{ 2.161.7 {{ * 0.004
Neutrophils (%) 59.367.2 64.068.4 { 71.466.6 {{{{ *** ,0.0001
Monocytes (%) 4.961.1 5.161.3 5.562.1 0.35
IL-1b (pg/mL) 1.161.7 0.961.7 1.864.6 0.49
IL-6 (pg/mL) 2.262.5 4.263.0 {{{ 6.265.9 {{{{ ,0.0001
TNFa (pg/mL) 4.268.4 2.162.6 1.862.0 0.73
TNFR-1 (pg/mL) 12526319 190961076 { 243061032 {{{ * 0.001
TNFR-2 (pg/mL) 15916466 261261386 {{ 310661277 {{{ 0.001
{p,0.05 vs. control; {{ p,0.01 vs. control; {{{ p,0.001 vs. control; {{{{ p,0.0001 vs. control * p,0.05 vs. patients on a beta-blocker; ** p,0.01 vs. patients on a beta-
blocker; *** p,0.001 vs. patients on a beta-blocker; **** p,0.0001 vs. patients on a beta-blocker. # p-values were calculated using the analysis of variance (ANOVA)
method of testing.
doi:10.1371/journal.pone.0006411.t004
Table 3. Table Regression.
IL-1b
(pg/mL)
IL-6
(pg/mL)
TNFa
(pg/mL)
TNFR-1
(pg/mL)
TNFR-2
(pg/mL)
LPS-stimulated
TNFa (pg/mL)
CRP
(mg/L)
Lymphocytes (%) NS r=20.242 NS r=20.345 r=20.287 NS NS
p=0.059 p=0.006 p=0.024
CD3
+ T cells (%) NS r=20.30 NS r=20.371 r=20.188 NS NS
p=0.022 p=0.004 p=0.158
CD4
+ T helper cells (%) NS NS NS r=20.368 r=20.245 NS NS
p=0.005 p=0.063
CD8
+ cytotoxic T cells (%) NS r=20.239 NS r=20.245 NS NS NS
p=0.071 p=0.064
CD19
+ B cells (%) NS NS r=20.224 r=20.282 r=20.224 NS NS
p=0.08 p=0.028 p=0.082
HLA-DR
+ lymphocytes (%) NS r=20.244 r=20.183 r=20.38 r=20.3 NS NS
p=0.062 p=0.165 p=0.003 p=0.021
Neutrophils (%) r=+0.169 r=+0.219 NS r=+0.217 r=+0.188 NS NS
p=0.189 p=0.087 p=0.09 p=0.144
Monocytes (%) NS NS r=+0.226 r=+0.201 r=+0.217 r=+0.206 NS
p=0.077 p=0.118 p=0.091 p=0.095
Creatinine (mmol/L) NS r=+0.307 r=+0.224 r=+0.637 r=+0.643 NS NS
p=0.015 p=0.08 p,0.0001 p,0.0001
NS=non-significant with p.0.2.
doi:10.1371/journal.pone.0006411.t003
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